Aytu Bioscience Inc (NASDAQ:AYTU) happens to be one of the best performing companies in the Urology sector. The business giant works on developing a wide range of remarkable medical products. These ones help with the treatment of acute medical conditions such as male infertility and urinary tract infections. It was today that the business guru spoke in relation to the expansion of its Primary Care Portfolio.
Current state of affairs
The business guru makes its entry into a $3 Billion Cough and Cold Market and hopes the move will pay off. The FDA a short while back gave its approval to Tuzistra® XR which happens to be a medical product from Tris Pharma. Aytu Bioscience moves in using the Tuzistra® XR license.
Tuzistra XR has chlorpheniramine polistirex and codeine polistirex in its constitutional make up. The company says that it awaits the FDA’s decision regarding one of its products pending before the body. Sources indicate that the company has already licensed the product.
The sales force says that Tuzistra XR will generate high levels of revenue provided the company’s management provides it with great support. In the previous year, Tuzistra XR performed remarkably. It managed to get about 40,000 prescriptions.
A closer outlook
Fundamentally, Tuzistra XR happens to be a combination of several substances. These include chlorpheniramine and an opiate agonist antitussive and these have great effects on patients struggling with acute medical conditions.
Some of the patients that get to benefit from the wide range of products include those struggling with the various upper respiratory allergies. A significant number of adults struggle with common colds on a daily basis and it gets worse as they advance in age. The medical provide seeks to come up with top-notch products that will help face out discomfort among patients.
Trusted reports indicate that the US cough cold prescription market is quite large in terms of the market valuation. On a yearly basis, about 35 million people prescribe to the wide range of the medical products. The same reports also indicate that the short-acting treatments dominate a great deal of the market.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.